|
Approximately 20,180 new cases of ovarian cancer will be diagnosed
in 2006, according to the American Cancer Society. Ovarian cancer
causes more deaths than any other cancer of the female reproductive
system.
Completed TELCYTA ovarian cancer clinical trials include:
ASSIST-1 (ASsessment of Survival In Solid Tumors-1): Phase 3 Randomized Study of TELCYTA (TLK286) Versus Liposomal Doxorubicin or Topotecan as Third-Line Therapy in Platinum-Refractory or Platinum-Resistant Ovarian Cancer.
ASSIST-3 (ASsessment of Survival In
Solid Tumors-3): Phase 3 Randomized Study of TELCYTA
(TLK286) plus carboplatin Versus Liposomal Doxorubicin as Second-Line
Therapy in Platinum-Refractory or Platinum-Resistant Ovarian Cancer.
Phase 2 Study of TELCYTA (TLK286) in Combination with Carboplatin
in Recurrent Ovarian Cancer.
Phase 2 Study of TELCYTA (TLK286) in Combination with Liposomal
Doxorubicin in Platinum-Refractory or Platinum-Resistant Ovarian
Cancer.
Additional information about ovarian cancer may be found at:
Ovarian Cancer National
Alliance or
National Ovarian Cancer Coalition
|
